HRP20230215T1 - Supstituirani policiklički derivati piridona i njihov predlijek - Google Patents
Supstituirani policiklički derivati piridona i njihov predlijek Download PDFInfo
- Publication number
- HRP20230215T1 HRP20230215T1 HRP20230215TT HRP20230215T HRP20230215T1 HR P20230215 T1 HRP20230215 T1 HR P20230215T1 HR P20230215T T HRP20230215T T HR P20230215TT HR P20230215 T HRP20230215 T HR P20230215T HR P20230215 T1 HRP20230215 T1 HR P20230215T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- group
- substituent group
- substituent
- alkyl
- Prior art date
Links
- -1 polycyclic pyridone derivatives Chemical class 0.000 title claims 3
- 239000000651 prodrug Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 claims 62
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000004452 carbocyclyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 5
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004437 phosphorous atom Chemical group 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004533 Endonucleases Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 101000900567 Pisum sativum Disease resistance response protein Pi49 Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 125000005094 alkyl carbonyl amino alkyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (8)
1. Spoj, naznačen time, da je predstavljen sljedećim formulama:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol;
pri čemu
P je vodik ili skupina PR odabrana od sljedećih formula:
a) -C(=O)-PR0,
b) -CC(=O)-PR1,
c) -C(=O)-L-PR1,
d) -C(=O)-L-O-PR1,
e) -C(=O)-L-O-L-O-PR1,
f) -C(=O)-L-O-C(=O)-PR1,
g) -C(=O)-O-PR2,
h) -C(=O)-N(-K)(PR2),
i) -C(=O)-O-L-O-PR2,
j) -C(PR3)2-O-PR4,
k) -C(PR3)2-O-L-O-PR4,
l) -C(PR3)2-O-C(=O)-PR4,
m) -C(PR3)2-O-C(=O)-O-PR4,
n) -C(PR3)2-O-C(=O)-N(-K)-PR4,
o) -C(PR3)2-O-C(=O)-O-L-O-PR4,
p) -C(PR3)2-O-C(=O)-O-L-N(PR4)2,
q) -C(PR3)2-O-C(=O)-N(-K)-L-O-PR4,
r) -C(PR3)2-O-C(=O)-N(-K)-L-N(PR4)2,
s) -C(PR3)2-O-C(=O)-O-L-O-L-O-PR4,
t) -C(PR3)2-O-C(=O)-O-L-N(-K)-C(=O)-PR4,
u) -C(PR3)2-O-P(=O)(-PR5)2,
v) -C(PR3)2-PR6,
w) -CC=N+(PR7)2)(-N(PR7)2),
x) -C(PR3)2-C(PR3)2-C(=O)-O-PR2,
y) -C(PR3)2-N(-K)-C(=O)-O-PR2,
z) -P(=O)(-PR8)(-PR9),
aa) -S(=O)2-O-PR10,
bb) PR11, i
cc) -C(PR3)2-C(PR3)2-O-PR2,
gdje L je ravni ili razgranati alkilen, ili ravni ili razgranati alkenilen;
K je vodik, ili alkil opcionalno supstituiran sa supstituentskom skupinom A;
PR0 je alkil opcionalno supstituiran sa supstituentskom skupinom A, ili alkenil opcionalno supstituiran sa supstituentskom skupinom A;
PR1 je karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, alkilamino opcionalno supstituiran sa supstituentskom skupinom A, ili alkilsulfanil opcionalno supstituiran sa supstituentskom skupinom A;
PR2 je alkil opcionalno supstituiran sa supstituentskom skupinom A, karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, karbociklilalkil opcionalno supstituiran sa supstituentskom skupinom A, heterociklilalkil opcionalno supstituiran sa supstituentskom skupinom A, ili trialkilsilil;
svaki PR3 je neovino vodik ili alkil;
svaki PR4 je neovisno alkil opcionalno supstituiran sa supstituentskom skupinom A, karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, alkilamino opcionalno supstituiran sa supstituentskom skupinom A, karbociklilalkil opcionalno supstituiran sa supstituentskom skupinom A, heterociklilalkil opcionalno supstituiran sa supstituentskom skupinom A, ili trialkilsilil;
svaki PR5 je neovisno vodik ili OBn;
PR6 je karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, ili heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A;
svaki PR7 je neovisno alkil opcionalno supstituiran sa supstituentskom skupinom A;
PR8 je alkiloksi opcionalno supstituiran sa supstituentskom skupinom A;
PR9 je alkiloksi opcionalno supstituiran sa supstituentskom skupinom A, alkilamino opcionalno supstituiran sa supstituentskom skupinom A, karbocikliloksi opcionalno supstituiran sa supstituentskom skupinom A, heterocikliloksi opcionalno supstituiran sa supstituentskom skupinom A, karbociklilamino opcionalno supstituiran sa supstituentskom skupinom A, ili heterociklilamino opcionalno supstituiran sa supstituentskom skupinom A;
PR8 i PR9 se mogu uzeti zajedno sa susjednim atomom fosfora u svrhu tvorbe heterocikla opcionalno supstituiranog sa supstituentskom skupinom A;
PR10 je alkil opcionalno supstituiran sa supstituentskom skupinom A, karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, karbociklilalkil opcionalno supstituiran sa supstituentskom skupinom A, ili heterociklilalkil opcionalno supstituiran sa supstituentskom skupinom A;
PR11 je alkil opcionalno supstituiran sa supstituentskom skupinom A, alkenil opcionalno supstituiran sa supstituentskom skupinom A, karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, ili heterociklilalkil skupina opcionalno supstituirana sa supstituentskom skupinom A;
supstituentska skupina A: okso, alkil, hidroksialkil, amino, alkilamino, karbociklil skupina, heterociklil skupina, karbociklilalkil, alkilkarbonil, halogen, hidroksi, karboksi, alkilkarbonilamino, alkilkarbonilaminoalkil, alkilkarboniloksi, alkiloksikarbonil, alkiloksikarbonilalkil, alkiloksikarboniloksi, alkilaminokarboniloksi, alkilaminoalkil, alkiloksi, cijano, nitro, azido, alkilsulfonil, trialkilsilil, i fosfo.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen jednom od sljedećih formula:
[image]
[image]
gdje P ima isto značenje kao što je opisano u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema patentnom zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, da PR je skupina odabrana od sljedećih formula:
a) -C(=O)-PR0,
b) -C(=O)-PR1,
g) -C(=O)-O-PR2,
h) -C(=O)-N(-K)(PR2),
i) -C(=O)-O-L-O-PR2,
l) -C(PR3)2-O-C(=O)-PR4,
m) -C(PR3)2-O-C(=O)-O-PR4,
o) -C(PR3)2-O-C(=O)-O-L-O-PR4,
v) -C(PR3)2-PR6, (osim benzil skupine)
x) -C(PR3)2-C(PR3)2-C(=O)-O-PR2,
y) -C(PR3)2-N(-K)-C(=O)-O-PR2, i
z) -P(=O)(-PR8)(-PR9),
pri čemu L je ravni ili razgranati niži alkilen;
K je vodik, ili alkil opcionalno supstituiran sa supstituentskom skupinom A;
PR0 je alkil opcionalno supstituiran sa supstituentskom skupinom A;
PR1 je karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, ili heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A;
PR2 je alkil opcionalno supstituiran sa supstituentskom skupinom A, karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, karbociklilalkil opcionalno supstituiran sa supstituentskom skupinom A, ili heterociklilalkil opcionalno supstituiran sa supstituentskom skupinom A;
svaki PR3 je neovsino vodik ili alkil;
PR4 je alkil opcionalno supstituiran sa supstituentskom skupinom A, karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, ili heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A;
PR6 je karbociklil skupina opcionalno supstituirana sa supstituentskom skupinom A, ili heterociklil skupina opcionalno supstituirana sa supstituentskom skupinom A;
PR8 je alkiloksi opcionalno supstituiran sa supstituentskom skupinom A;
PR9 je alkiloksi opcionalno supstituiran sa supstituentskom skupinom A, alkilamino opcionalno supstituiran sa supstituentskom skupinom A, karbocikliloksi opcionalno supstituiran sa supstituentskom skupinom A, heterocikliloksi opcionalno supstituiran sa supstituentskom skupinom A, karbociklilamino opcionalno supstituiran sa supstituentskom skupinom A, ili heterociklilamino opcionalno supstituiran sa supstituentskom skupinom A; i
PR8 i PR9 se mogu uzeti zajedno sa susjednim atomom fosfora u svrhu tvorbe heterocikla opcionalno supstituiranog sa supstituentskom skupinom A;
supstituentska skupina A: okso, alkil, alkilamino, karbociklil skupina, heterociklil skupina, alkilkarbonil, halogen, hidroksi, alkilkarbonilamino, alkilkarboniloksi, alkiloksikarbonil, alkiloksikarbonilalkil, alkilaminokarboniloksi, alkiloksi, nitro, azido, alkilsulfonil, i trialkilsilil.
4. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen sa sljedećim formulama:
[image]
ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema patentnom zahtjevu 4, naznačen time, da je predstavljen sa sljedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol.
6. Farmaceutski pripravak, naznačen time, da sadrži spoj u skladu s jednim od patentnih zahtjeva 1 do 5, ili njegovu farmaceutski prihvatljivu sol.
7. Farmaceutski pripravak prema patentom zahtjevu 6, naznačen time, da je za uporabu u liječenju ili prevenciji infekcije virusnom gripom.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u liječenju ili prevenciji bolesti uzrokovane virusom koji ima endonukleazu ovisnu o kapi.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015090909 | 2015-04-28 | ||
| JP2015236844 | 2015-12-03 | ||
| PCT/JP2016/063139 WO2016175224A1 (ja) | 2015-04-28 | 2016-04-27 | 置換された多環性ピリドン誘導体およびそのプロドラッグ |
| EP16786500.5A EP3290424B1 (en) | 2015-04-28 | 2016-04-27 | Substituted polycyclic pyridone derivatives and prodrug thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230215T1 true HRP20230215T1 (hr) | 2023-04-14 |
Family
ID=56701691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230215TT HRP20230215T1 (hr) | 2015-04-28 | 2016-04-27 | Supstituirani policiklički derivati piridona i njihov predlijek |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230287004A1 (hr) |
| JP (1) | JP5971830B1 (hr) |
| KR (1) | KR102409779B1 (hr) |
| CN (1) | CN113004304B (hr) |
| CY (1) | CY1123920T1 (hr) |
| DK (1) | DK3290424T3 (hr) |
| ES (1) | ES2938877T3 (hr) |
| HR (1) | HRP20230215T1 (hr) |
| LT (1) | LT3290424T (hr) |
| MX (1) | MX2021006404A (hr) |
| MY (1) | MY189144A (hr) |
| PH (1) | PH12017501909A1 (hr) |
| PL (1) | PL3290424T3 (hr) |
| RS (1) | RS64012B1 (hr) |
| SI (1) | SI3290424T1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2984130C (en) * | 2015-04-28 | 2021-07-20 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and prodrug thereof |
| SG11201804348SA (en) * | 2015-12-15 | 2018-06-28 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| SG11201810655QA (en) * | 2016-06-20 | 2019-01-30 | Shionogi & Co | Method for producing substituted polycyclic pyridone derivative and crystal of same |
| CN110494141A (zh) | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物 |
| CN111201222A (zh) | 2017-10-11 | 2020-05-26 | 大金工业株式会社 | 具有不饱和基团的环状碳酸酯的制造方法和新型环状碳酸酯 |
| SG11202011447UA (en) * | 2018-01-17 | 2020-12-30 | Jiangxi Caishi Pharmaceutical Technology Co Ltd | Pyridone derivative, composition and use as antiviral drug thereof |
| CN110041327B (zh) * | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| AR115354A1 (es) * | 2018-04-24 | 2020-12-23 | Shionogi & Co | Forma de dosis sólida con excelente estabilidad |
| WO2020055858A1 (en) * | 2018-09-10 | 2020-03-19 | Cocrystal Pharma, Inc. | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication |
| RU2720305C1 (ru) * | 2019-05-07 | 2020-04-28 | Андрей Александрович Иващенко | Замещенный 3,4,12,12а-тетрагидро-1Н-[1,4]оксазино[3,4-c]пиридо[2,1-f] [1,2,4]триазин-6,8-дион, фармацевтическая композиция, способы их получения и применения |
| CA3142030A1 (en) | 2019-07-11 | 2021-01-14 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Compounds useful to treat influenza virus infections |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2280435A (en) | 1993-07-29 | 1995-02-01 | Merck & Co Inc | Anti-viral agent |
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| CA2626956A1 (en) | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
| TWI518084B (zh) * | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| PT2444400T (pt) | 2009-06-15 | 2018-06-06 | Shionogi & Co | Derivado de carbamoilpiridona policíclico substituído |
| JP5766690B2 (ja) | 2010-04-12 | 2015-08-19 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有するピリドン誘導体 |
| SI2620436T1 (en) * | 2010-09-24 | 2018-08-31 | Shionogi & Co., Ltd. | A prodrug substituted polycyclic carbamoyl pyridone derivative |
| US8859290B2 (en) | 2011-07-22 | 2014-10-14 | Rutgers, The State University Of New Jersey | Inhibitors of influenza endonuclease activity and tools for their discovery |
| US20130102600A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| WO2013174930A2 (en) | 2012-05-23 | 2013-11-28 | Savira Pharmaceuticals Gmbh | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| CN104619699A (zh) | 2012-08-06 | 2015-05-13 | 萨维拉制药有限公司 | 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途 |
| WO2014024056A1 (en) * | 2012-08-06 | 2014-02-13 | Daiichi Sankyo Company, Limited | Pyrrolidine derivatives with antibacterial properties |
| US9573938B2 (en) | 2012-09-11 | 2017-02-21 | Rutgers, The State University Of New Jersey | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones |
| US9701638B2 (en) | 2012-11-09 | 2017-07-11 | Rutgers, The State University Of New Jersey | Therapeutic hydroxyquinolones |
| CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| WO2014108408A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| JP2016508145A (ja) | 2013-01-08 | 2016-03-17 | ザヴィラ ファーマシューティカルズ ゲーエムベーハー | ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 |
| PE20160661A1 (es) | 2013-09-12 | 2016-08-05 | Alios Biopharma Inc | Compuesto de azapiridona y sus usos de los mismos |
| CA2984130C (en) * | 2015-04-28 | 2021-07-20 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and prodrug thereof |
| SG11201804348SA (en) | 2015-12-15 | 2018-06-28 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| CN110494141A (zh) * | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物 |
-
2016
- 2016-04-27 HR HRP20230215TT patent/HRP20230215T1/hr unknown
- 2016-04-27 RS RS20230158A patent/RS64012B1/sr unknown
- 2016-04-27 CN CN202110303513.XA patent/CN113004304B/zh active Active
- 2016-04-27 ES ES16786500T patent/ES2938877T3/es active Active
- 2016-04-27 MY MYPI2017703817A patent/MY189144A/en unknown
- 2016-04-27 LT LTEPPCT/JP2016/063139T patent/LT3290424T/lt unknown
- 2016-04-27 SI SI201631657T patent/SI3290424T1/sl unknown
- 2016-04-27 PL PL16786500.5T patent/PL3290424T3/pl unknown
- 2016-04-27 MX MX2021006404A patent/MX2021006404A/es unknown
- 2016-04-27 DK DK16786500.5T patent/DK3290424T3/da active
- 2016-04-27 JP JP2016535247A patent/JP5971830B1/ja active Active
- 2016-04-27 KR KR1020197012391A patent/KR102409779B1/ko active IP Right Grant
-
2017
- 2017-10-19 PH PH12017501909A patent/PH12017501909A1/en unknown
-
2021
- 2021-03-08 CY CY20211100196T patent/CY1123920T1/el unknown
-
2022
- 2022-12-13 US US18/080,247 patent/US20230287004A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190049916A (ko) | 2019-05-09 |
| PL3290424T3 (pl) | 2023-05-08 |
| JP5971830B1 (ja) | 2016-08-17 |
| KR102409779B1 (ko) | 2022-06-16 |
| ES2938877T3 (es) | 2023-04-17 |
| MX2021006404A (es) | 2022-08-02 |
| PH12017501909B1 (en) | 2018-03-05 |
| PH12017501909A1 (en) | 2018-03-05 |
| MY189144A (en) | 2022-01-28 |
| CY1123920T1 (el) | 2021-06-25 |
| DK3290424T3 (da) | 2023-02-06 |
| CN113004304A (zh) | 2021-06-22 |
| SI3290424T1 (sl) | 2023-03-31 |
| JPWO2016175224A1 (ja) | 2017-05-18 |
| RS64012B1 (sr) | 2023-03-31 |
| US20230287004A1 (en) | 2023-09-14 |
| CN113004304B (zh) | 2022-03-18 |
| LT3290424T (lt) | 2023-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230215T1 (hr) | Supstituirani policiklički derivati piridona i njihov predlijek | |
| FI3290424T3 (fi) | Substituoituneita polysyklisiä pyridonijohdannaisia ja niiden aihiolääkkeitä | |
| IL264709B2 (en) | Pharmaceutical preparations containing a modified polycyclic pyridone derivative and a hemane prodrug | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20221536T1 (hr) | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina | |
| HRP20240218T1 (hr) | Modulatori integriranog puta stresa | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| PH12016501829B1 (en) | Plant disease control composition and method for controlling plant disease by application of same | |
| HRP20230342T1 (hr) | Kationski lipid koji se može ionizirati za isporuku rna | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| AR102468A1 (es) | Métodos para la preparación de ribósidos | |
| HRP20181036T1 (hr) | 2,6-supstituirani derivati purina i njihova upotreba u liječenju proliferativnih poremećaja | |
| HRP20171050T1 (hr) | Derivati 1,3-dihidro-2h-benzimidazol-2-ona supstituirani s heterociklima kao antivirusna sredstva za respiratorni sincicijski virus | |
| HRP20220920T1 (hr) | Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom | |
| HRP20161060T1 (hr) | Nitrogenizirani heterociklički spoj te agrikulturni ili hortikulturni fungicid | |
| IN2014DN05868A (hr) | ||
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| HRP20170025T1 (hr) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| WO2012061428A3 (en) | Nicotinamides as jak kinase modulators | |
| JP2016523955A5 (hr) |